A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB WITH AND WITHOUT TIRAGOLUMAB IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA

Go Back to All Clinical Trials

A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB WITH AND WITHOUT TIRAGOLUMAB IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA

Brief description of study

The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC).

Clinical Study Identifier: s23-00376

ClinicalTrials.gov Identifier: NCT05904886

Principal Investigator: Jennifer Wu.

Other Investigators: Jason E Sandler, Daniel J Becker, Cristian C Papazoglu Statescu, Andrea Popescu-Martinez, Jennifer Chuy, Kristen Spencer, Keriann M Scavone, Nina Beri, Kenneth Csehak, Paul E. Oberstein, Theresa Ryan, Rafael Winograd, Shun Yu, Mary Lynn R Nierodzik.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies